綠葉製藥(02186.HK)精神分裂症新藥「瑞欣妥」開出首張處方
綠葉製藥(02186.HK)表示,自主研發的注射用利培酮微球「瑞欣妥」於3月1日在山東開出首張處方,正式面向全國多個省市的醫院和藥房供藥。
瑞欣妥用於治療急性和慢性精神分裂症以及其他各種精神病性狀態的明顯的陽性症狀和明顯的陰性症狀,可減輕與精神分裂症有關的情感症狀。
集團表示,瑞欣妥從獲得國家藥品監督管理局的上市批准到首位患者的供應用藥,僅用40多天,目前全球註冊申報工作在同步開展,產品已在美國進入新藥上市申請階段,並在歐洲開展關鍵臨床研究,其專利在中國、美國、歐洲、日本、韓國、俄羅斯、加拿大、澳大利亞均獲得授權,專利期至2032年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.